InflaRx IFRX
NASDAQ IFRX
$2.10 +0.08 (+3.96%)
At close: Aug 21, 2026 · 4:00 PM EDT

InflaRx (IFRX) Long-Term Investments (2017 - 2026)

InflaRx (IFRX) posted Long-Term Investments of $9.7 million for Q1 2026, up 3401.34% sequentially from $276312.5 in Q4 2025, and down 47.94% YoY from $18.6 million in Q1 2025.

InflaRx (IFRX) Long-Term Investments (2017 - 2026) Analysis & Trends

InflaRx has reported Long-Term Investments for 10 years, with the latest figure at $9.7 million in Q1 2026.

  • Quarterly Long-Term Investments fell 47.94% year-over-year to $9.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.7 million (down 47.94% YoY) and the FY2025 annual result came in at $55.9 million, down 41.18% from the prior year.
  • Long-Term Investments improved to $9.7 million in Q1 2026 per IFRX's latest filing, from $276312.5 in the prior quarter.
  • Over five years, Long-Term Investments peaked at $8553.5 billion in Q1 2023 and troughed at $276312.5 in Q4 2025.
  • A 5-year average of $777.6 billion and a median of $45.7 million in 2025 frame the typical range for Long-Term Investments.
  • The sharpest annual moves came in 2023 and 2024: Long-Term Investments jumped 3042.29% in 2023, then tumbled 96.45% in 2024.
  • Over 5 years, Long-Term Investments stood at $3.0 million in 2022, then soared by 3042.29% to $93.0 million in 2023, then sank by 96.45% to $3.3 million in 2024, then plunged by 91.64% to $276312.5 in 2025, then jumped by 3401.34% to $9.7 million in 2026.
  • According to Business Quant data, Long-Term Investments over the past three periods registered $9.7 million, $276312.5, and $45.7 million for Q1 2026, Q4 2025, and Q2 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Investments (Qtr)
1 Vertex Pharmaceuticals 139.13 Bn 131.28 Bn 2.84 Bn 5.79 Bn
2 Regeneron Pharmaceuticals 85.77 Bn 77.77 Bn 3.93 Bn 9.83 Bn
3 Argenx Se 64.64 Bn 59.46 Bn 1.37 Bn -
4 Moderna 58.29 Bn 53.16 Bn 52.00 Mn 1.77 Bn
5 BeOne Medicines 41.92 Bn 36.82 Bn 1.53 Bn -
6 Alnylam Pharmaceuticals 31.58 Bn 28.28 Bn 992.69 Mn 22.17 Mn
7 BioNTech SE 28.12 Bn 9.73 Bn 668.28 Mn -
8 Insmed 27.39 Bn 26.22 Bn 358.27 Mn -
9 Royalty Pharma 27.27 Bn 26.43 Bn - 372.10 Mn
10 InflaRx 140.30 Mn -43.96 Mn 2.74 Bn -

Historic Data

Download Data
DateValue
Mar 31, 2026 9.67 Mn
Dec 31, 2025 276,312.50
Jun 30, 2025 45.73 Mn
Mar 31, 2025 18.58 Mn
Dec 31, 2024 3.30 Mn
Jun 30, 2024 59.98 Mn
Dec 31, 2023 93.00 Mn
Jun 30, 2023 109.65 Mn
Mar 31, 2023 8,553.54 Bn
Dec 31, 2022 2.96 Mn
Jun 30, 2022 89.95 Mn
Dec 31, 2021 31.12 Mn
Sep 30, 2021 31,505.85 Bn
Dec 31, 2020 324,622.37
Sep 30, 2020 318.24 Mn
Jun 30, 2020 300.29 Mn
Mar 31, 2020 301,064.04
Dec 31, 2019 -83,617.62
Sep 30, 2019 303,490.44
Jun 30, 2019 325,855.34